Disclaimer: At the time of this video, I do NOT own shares of RLFTF. I am not paid by NeuroRx or any biotech company and I was NOT paid for this interview. All opinions and thoughts expressed in these videos are mine and not influenced by anyone else.
Excellent interview! Great job Dr. Yo and excellent questions. All the information we received was very motivating and hopeful. Sounds like Dr Javitt has a few big partnerships to be announced! Extremely excited for the trials to begin! Keep up the good work all of you! Let’s save the world with RLF-100!
I'm glad that Dr. Javitt keeps pointing out that this could be the placebo effect. As much as we want to find a treatment for those disease, we have to keep our expectations reasonable and always keep in mind that we need randomized peer reviewer studies to ensure that the results aren't due to chance or placebo.
@@serge1011 Not necessarily. Placebos have been shown to have a statistically significant effect on patients with little to no conscious awareness or understanding that they've received a placebo. Just because a patient isn't consciously aware of something doesn't mean it didn't trigger a subconscious or unconscious reaction. There have even been some studies showing that the placebo effect work on animals that have no comprehension of what placebos are or what pills do.
after covid is over this will be taken to enhance durability during high cardio sessions in pro sports, if it is true that it enhanced oxygen in bloodcells^^
James James nonsense. I have to say I don’t know dr Yo or his channel but this was a good in depth interview. Stockprice was already 10x of 15x at the time of this publication. He has very small subscriber base and not many views so hard to see this as stock pumping.
Dr. Yo! Do you have any thoughts or concerns about the half life of the drug when it is inhaled? Would love to hear you ask about that on your next interview!
Hey All! For those who do not know VIP is the last ( and most important) step in treating CIRS. CIRS = Chronic Inflammation Response Syndrome. Anyone who has a Lyme infection or deals with mold knows about VIP. A few papers were put out by Dr. Richie Shoemaker, Dr. Andrew Heymen about CIRS. This is very accessible information. In addition, a spanish group put out a paper about neurodegenerative problems and VIP. See Maria Morell, " VIP in Neurological Diseases: More Than A Neuropeptide. The FDA has considered banning it, I'm glad it now has another use and attempts to ban it will be much harder now.
Plz include.indian generic Pharma company for rlf 100 production like in case of remdisivir they are best to make it affordable..dr.yo please lobby for this....🙏🙏🙏
Dr. Yoooooo! Thanks for responding. You're awesome man. I'm a dolphins fan. Hey I'm a fantasy champ so if you ever need advice hit my up. I love the bucs this year. I have all of the players on fantasy team. Dr Yo is there anyway you could make a comment on my channel. If not I understand but my subscribers would be floored and I would be incredibly honored as I'm trying to help promote this drug. Anything, I dont care if you said, "boo". I'll put it in my captions and I'll brag about it, in a none bragging way lol if you could do that. If not thanks for the reply. So cool.
That's amazing. I'm gonna a video on it tomorrow when I do my report. I'll post it on every board I'm on too. Thanks Dr. Yo. It means so much. I owe you bigtime. If there is anything you want me to point out just put it in the comment and I'll make sure and stress that point tomorrow.
Dr. Yo, do you think you could comment about RANTES on my video as I'm interested to spread that info as well. And any other words your willing to share would be greatly appreciated. If you too busy, no worries but thank you.
Has the bump to Intermediate-Size Patient Population and Treatment INDs and Protocol from the Individual (or Single) Patient Expanded Access made it faster or slower for one individual to get emergency access to aviptadil? I'm sure overall it will increase availability but I'm unsure about the short term access. And when did this change take place?
The move to Intermediate Population Expanded Access gives hospitals a simple protocol and set of forms to complete for rapid site qualification. The single patient program required far more paperwork for hospitals and doctors.
What's the difference between Aviptadil and Leronlimab? Next time, considering LL's multiple indications, could VIP also be used for cancer, Parkinson's, etc.?
Leronlimab is a monoclonal antibody that targets and occupies CCR5. VIP is a peptide you’re body makes naturally. 70% is found in your lungs. Aviptadil is a synthetic version of VIP that acts like an antiviral to protect the lung tissue and also as an immunomodulator
@@michellemosley3177 - I will have to check with Dr. Been. I do know from immunology textbooks we know that VIP inhibits RANTES (CCL5) the chemokine that binds to CCR5. I posted the immunology article describing this MOA on one of my tweets on twitter.
All of the monoclonal antibodies ("...mab" drugs) are designed to absorb and inactivate inflammatory cytokines that are circulating in the body. VIP blocks the synthesis of cytokines in the first place. Unlike all of the mabs, VIP also blocks replication of the coronavirus in the human lung cell, which is an effect not seen with monoclonal antibody drugs
@@JJ1956DC This is amazing news. I certainly hope this becomes widely available much sooner than later. In addition to Covid, would Aviptadil also help in other lung related issues such as asthma?
Love your videos, Dr. Yo. Wish you had time to make more. "Patients will be randomized to intravenous Aviptadil will receive escalating doses from 50 -150 pmol/kg/hr over 12 hours." - clinicaltrials.gov Other future trials Robert I Grossman School of Medicine / NYU Langone Medical Center -NYR Thomas Jefferson University Hospital - NYC Rambam Health Care Campus Haifa, Israel, 3109601 Not yet recruiting
Disclaimer: At the time of this video, I do NOT own shares of RLFTF. I am not paid by NeuroRx or any biotech company and I was NOT paid for this interview. All opinions and thoughts expressed in these videos are mine and not influenced by anyone else.
You want me to buy some for you?
Excellent interview! Great job Dr. Yo and excellent questions. All the information we received was very motivating and hopeful. Sounds like Dr Javitt has a few big partnerships to be announced! Extremely excited for the trials to begin! Keep up the good work all of you! Let’s save the world with RLF-100!
Dr. Yogendra, Dr. Javitt, thank you so much for your fantastic work! you're great!
and have to add, very excited for the interview with you and Dr. Javitt and Dr. Jusuf
Good interview - thank you. This RLF-100 is very promising for patients. Also a good time to invest in the company Relief Therapeutics
This drug sounds amazing! It can help a lot of people! So excited to see FDA approval for use in Covid-19 patients.
Just awaiting trial results and hopefully FDA approval soon thereafter.
Thank you Dr Yo and Dr Javitt for this interview. I’m encouraged to have this added to our “toolbox”.
WOWZA. Promising development for stopping replication of the virus in its track and it seems life saving for the severely ill with covid!
Looking at RFL-100 (Aviptadil) progress at the trail phase, m sure it will get FDA Approval. 👍
Thank you very much Dr. Yo this was very informative, keep up the great work.
Dr. YO Thank you so much for this very informative interview. Hope this will end this pandemic
I'm glad that Dr. Javitt keeps pointing out that this could be the placebo effect. As much as we want to find a treatment for those disease, we have to keep our expectations reasonable and always keep in mind that we need randomized peer reviewer studies to ensure that the results aren't due to chance or placebo.
I really respected him about that point- he is deeply grounded in the science and medicine.
Placebo effect wouldnt be a problem at people who are at sleep.
@@serge1011 Not necessarily. Placebos have been shown to have a statistically significant effect on patients with little to no conscious awareness or understanding that they've received a placebo. Just because a patient isn't consciously aware of something doesn't mean it didn't trigger a subconscious or unconscious reaction. There have even been some studies showing that the placebo effect work on animals that have no comprehension of what placebos are or what pills do.
Thank you for this great interview!
Adding this to my portfolio
Dr .yogendra proud of you bro ...make video on yourself and your journey...👍
This guy is a real talent as well as know how to keep FDA happy. One of the most corrupted organization in USA
Excellent informative talk, thank u very much both of u.
This drug has a lot of potential. Thank you Dr. Javitt and thank you Dr. Yogendra for arranging this interview.
Thanks Dr Yo, looking forward to next session with rlf team. ...doing the work and foresight of prepared distribution if effective.
Great job Dr Yo! Thank you very much!!!
Very good interview. What date will Dr. Yousif's follow up results of the 21 patients be released?
You Rawk DR. Yo.. Keep these coming
Hi, very interesting information! Hope to hear more about this medicine. Sounds promising, even if we’re not sure yet.
Nostalgic to watch this again now….after NIH trial halt due to futility. Stock price was $45 and is now $0.56.
after covid is over this will be taken to enhance durability during high cardio sessions in pro sports, if it is true that it enhanced oxygen in bloodcells^^
Hi Dr m from Mumbai.. your vedio is very informative...👍
Get some $RLFTF!!! It may be a CURE!!!
dr been and yo are scammers ...stock pumpers...failed cydy same bums
James James nonsense. I have to say I don’t know dr Yo or his channel but this was a good in depth interview. Stockprice was already 10x of 15x at the time of this publication.
He has very small subscriber base and not many views so hard to see this as stock pumping.
Dr. Yo! Do you have any thoughts or concerns about the half life of the drug when it is inhaled? Would love to hear you ask about that on your next interview!
I second this!
We have a successful investment here Dr. Javitt credentials are top notch and we have heavy hitters in our line-up.
Hey All! For those who do not know VIP is the last ( and most important) step in treating CIRS. CIRS = Chronic Inflammation Response Syndrome. Anyone who has a Lyme infection or deals with mold knows about VIP. A few papers were put out by Dr. Richie Shoemaker, Dr. Andrew Heymen about CIRS. This is very accessible information. In addition, a spanish group put out a paper about neurodegenerative problems and VIP. See Maria Morell, " VIP in Neurological Diseases: More Than A Neuropeptide. The FDA has considered banning it, I'm glad it now has another use and attempts to ban it will be much harder now.
Plz include.indian generic Pharma company for rlf 100 production like in case of remdisivir they are best to make it affordable..dr.yo please lobby for this....🙏🙏🙏
When is the follow up interview/discussion?
Hey Dr yo. Just watched that video for the 10th time. Awesome job. What is your favorite football team? Do you play fantasy football?
TB Bucs! Brady Nation now! I am terrible with fantasy because my ADHD kicks in and I stop playing after week 4
Dr. Yoooooo! Thanks for responding. You're awesome man. I'm a dolphins fan. Hey I'm a fantasy champ so if you ever need advice hit my up. I love the bucs this year. I have all of the players on fantasy team.
Dr Yo is there anyway you could make a comment on my channel. If not I understand but my subscribers would be floored and I would be incredibly honored as I'm trying to help promote this drug. Anything, I dont care if you said, "boo". I'll put it in my captions and I'll brag about it, in a none bragging way lol if you could do that. If not thanks for the reply. So cool.
m.th-cam.com/video/89_NhlWfFTs/w-d-xo.html
Here is my latest video. If you could say a few words I'd be honored an my subscribers would go nuts.
Definitely man. I’ll hop on over and check out your channel!
That's amazing. I'm gonna a video on it tomorrow when I do my report. I'll post it on every board I'm on too. Thanks Dr. Yo. It means so much. I owe you bigtime. If there is anything you want me to point out just put it in the comment and I'll make sure and stress that point tomorrow.
Did you ask if the MOA of Aviptadil works on the CCL5 and reduces rantes???
I didn't get into the details but hoping in the next discussion with Dr. Javitt and Dr. Yusuf we can talk "shop" a little more.
dr. yo what is your feeling about when the results of the current tests come. approximately? thank you for your feedback. ps your videos are great.
Your guess is as good as mine.
Dr. Yo, do you think you could comment about RANTES on my video as I'm interested to spread that info as well. And any other words your willing to share would be greatly appreciated. If you too busy, no worries but thank you.
Has the bump to Intermediate-Size Patient Population and Treatment INDs and Protocol from the Individual (or Single) Patient Expanded Access made it faster or slower for one individual to get emergency access to aviptadil? I'm sure overall it will increase availability but I'm unsure about the short term access. And when did this change take place?
The move to Intermediate Population Expanded Access gives hospitals a simple protocol and set of forms to complete for rapid site qualification. The single patient program required far more paperwork for hospitals and doctors.
@@JJ1956DC Thanks Dr. Javitt. Can you guys do an update on the 21 patients at Houston Methodist?
Dr Yo, interesting to know if leronlimab and aviptadil can be used jointly?
It has been brought up by many. It sounds potentially good on paper but studies will need to be done first.
What's the difference between Aviptadil and Leronlimab?
Next time, considering LL's multiple indications, could VIP also be used for cancer, Parkinson's, etc.?
Leronlimab is a monoclonal antibody that targets and occupies CCR5.
VIP is a peptide you’re body makes naturally. 70% is found in your lungs. Aviptadil is a synthetic version of VIP that acts like an antiviral to protect the lung tissue and also as an immunomodulator
@@DoctorYogendra Dr. Mobeen's video showed that they both work on CCR5. Do they do that differently?
@@michellemosley3177 - I will have to check with Dr. Been. I do know from immunology textbooks we know that VIP inhibits RANTES (CCL5) the chemokine that binds to CCR5. I posted the immunology article describing this MOA on one of my tweets on twitter.
All of the monoclonal antibodies ("...mab" drugs) are designed to absorb and inactivate inflammatory cytokines that are circulating in the body. VIP blocks the synthesis of cytokines in the first place. Unlike all of the mabs, VIP also blocks replication of the coronavirus in the human lung cell, which is an effect not seen with monoclonal antibody drugs
@@JJ1956DC This is amazing news. I certainly hope this becomes widely available much sooner than later. In addition to Covid, would Aviptadil also help in other lung related issues such as asthma?
I'm gonna say some nice words about you today on my video. Should be out about 5pm so if you get a chance take a look.
2 thumbs down are from people with no future
Why would this company have hired an eye surgeon?
Love your videos, Dr. Yo. Wish you had time to make more. "Patients will be randomized to intravenous Aviptadil will receive escalating doses from 50 -150 pmol/kg/hr over 12 hours." - clinicaltrials.gov
Other future trials
Robert I Grossman School of Medicine / NYU Langone Medical Center -NYR
Thomas Jefferson University Hospital - NYC
Rambam Health Care Campus Haifa, Israel, 3109601 Not yet recruiting